PD-2024.1

I. General Information	General Information OMB Approved # 0938-0944 (Expires: 8/31/2025)										
Contract Number:		4. Contract Yr:	2024	7. Plan Name:		10. VBID-D:	N	12. PD Region:		15. PMM:	N
2. Plan ID:		5. Org. Name:		8. Plan Type:				13. PD Benefit Type:		16. SSM:	N/A
Segment ID:		6. SNP:		9. Enrollee Type:		11. ESRD-SNP:	N	14. SNP Type:	N/A		

Plan ID:		5. Org. Name:			8. Plan Type:					PD Benefit Type:	
3. Segment ID:		6. SNP:			9. Enrollee Type:			11. ESRD-SNP:	N	14. SNP Type:	N/A
	<u>. </u>	•									
II. Base Period Background I	Information										
	illorillation			2- T-+- M M		1 0	C Manaina	Casta Diag Cas ID	NA	Casta Diag Cas ID	NA
Time Period Definition Incurred from		=		2a. Total Member M		0	5. Mapping	Contr-Plan-Seg ID	Member Months	Contr-Plan-Seg ID	Member Month
Incurred from:		_		2b. LIS Member Mor	IUIS						
Incurred to:				3. Risk Score							
Paid through:				4. Completion Factor	r						
III. Part D Claims Experience											
	(d)	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(I)	(m)	(n)
	Total Count in Interva	l	Cumulative								
								Adjustmer	nts to Reflect Pt.	D Coverage	
Allowed			Total	Total	Average	Average	Average	Supplemental	Reimb for	Reimb	Net Plan
Claim	# of	Member	Number of	Allowed	Allowed Amount	Paid Amount	Cost Sharing	C.S. Reduc.	LIS	for Fed Reins.	Responsibility
Interval	Members	Months	Scripts	Dollars	per Member	per Member	per Member	per Member	per Member	per Member	per Member
interval	Wellibers	WOTHIS	Scripts	Dollars	per wernber	per Member	per member	per werriber	per member	per werriber	per wember
		I			40.00						40
1. \$0 2. \$1-\$479 3. \$480-\$4,429 4. \$4,430-Catastrophic * 5. Above Catastrophic *					\$0.00						\$0.0
2. \$1-\$479					\$0.00						\$0.
3. \$480-\$4,429					\$0.00						\$0.0
\$4,430-Catastrophic *					\$0.00						\$0.0
Above Catastrophic *					\$0.00						\$0.0
6. Subtotal	0		0 0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.0
7. % OON	•	•	•								•
,, ,, ,,											
8. PMPM Values				\$0.00		\$0.00		\$0.00	\$0.00	\$0.00	\$0.
				φ0.00	<u>'</u>			φυ.υυ	φυ.υυ	φ0.00	\$0.0
9. Minus Rebates						\$0.00					
10. Plus Part D as Secondary						\$0.00					\$0.0
11. Net Average Paid Amount						\$0.00		\$0.00	\$0.00	\$0.00	\$0.0
Non-covered Supplemental	-					\$0.00					
Rebates on Supplemental D)rugs					\$0.00					
14. Net PMPM on Supplemen	ital Drugs					\$0.00					\$0.0
* See Instructions for Completin	ng the Prescription Drug	Plan BPT for CY2024									
oce instructions for completing	ig the r resoription brug	11011 01 1101 012024	•								
IV. PMPM Non-Benefit Exper	1000					VI. PMPM Income	Statement Sumn	arv		(m)	
IV. FIMENI NOII-Bellelit Exper	1505			(=)				iai y			1
				(g)	7	Premium Revenu	ue			\$0.00	
				Total		LIS Reimb.				\$0.00	
 Sales and Marketing 						Fed Reins.				\$0.00	
Direct Administration						Allocated Buy-Do	own*				
3. Indirect Administration						5. Total Revenue				\$0.00	
4. Net Cost of Private Reinsur	rance										
						6. Pharmacy Claims	s			\$0.00	1
						7. Non-Benefit Exp				\$0.00	
5. Total Non-Benefit Expens	ses			\$0.00		8. Total Expenses				\$0.00	1
	,			φυ.υυ	1	o. Total Expelises	•			φυ.υυ	ĺ
V. PMPM Premium Revenue		(-)	(0)	(-)						*	ĺ
		(e)	(f)	(g)	7	9. Gain/(Loss) Inc	luding Buy-Down			\$0.00	j
ĺ		Basic	Supplemental	Total	1						
 CMS Part D Payment 				\$0.00		* MA rebate dollars	to buy-down Part	D premium (not true	revenue)		
2. LI Premium Subsidy				\$0.00							
3. Member Premium				\$0.00			Total Non-LI Bra	nd Discount Amoun	t		
1					-1						4

PRA Disclosure Statement According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0944. The time required to complete this information collection is estimated to average 30 hours per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

\$0.00

\$0.00

\$0.00

5. Total Premium

I. General Information

Contract Number:	4. Contract Yr:	2024	7. Plan Name:	10. VBID-D:	N	12. PD Region:	15. PMM:	N
2. Plan ID:	5. Org. Name:		8. Plan Type:			PD Benefit Type:		
Segment ID:	6. SNP:		Enrollee Type:	11. ESRD-SNP:	N	14. SNP Type:	N/A	

II. Utilization for Covered Part D Drugs

	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(I)	(m)	(n)	(o)
		Base Period			Compon	ents of Utilization	Change				
	# of								Total	Projected	
	Scripts/	Allowed	PMPM	Trend in	Formulary	Risk	Induced	Other	Utilization	Scripts/	
Type of Script	1000	per Script	Allowed	Scripts/1000	Change	Change	Utilization*	Change	Change	1000	Covariance
Retail Generic			\$0.00						0.000	0	0.000
Retail Preferred Brand			\$0.00						0.000	0	0.000
3. Retail Non-Preferred Brand			\$0.00						0.000	0	0.000
4. Retail Specialty			\$0.00						0.000	0	0.000
5. Mail Order Generic			\$0.00						0.000	0	0.000
6. Mail Order Preferred Brand			\$0.00						0.000	0	0.000
7. Mail Order Non-Preferred Brand			\$0.00						0.000	0	0.000
8. Mail Order Specialty			\$0.00						0.000	0	0.000
a Tarak Baratt		00.00	# 0.00	0.000	0.000	0.000	0.000	0.000	0.000		0.000
9. Total Retail	0	\$0.00	\$0.00			0.000	0.000	0.000	0.000		0.000
10. Total Mail Order	0	\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
11. Total Generic	0	\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
12. Total Brand (Preferred and Non-Preferred)	0	\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
13. Total Specialty	0	\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
14. Total	0	\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000

^{*}Adjustment to remove impact of induced utilization due to supplemental coverage

III. Cost for Covered Part D Drugs

III. Cost for Covered Part D Drugs								IV. Projected	Allowed PMPN	1		
	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(I)	(m)	(n)	(o)	(p)
		Compon	ents of Unit Cost	Change		Projected	Projected	Manual	Manual	Manual		Blended
	Inflation	Discount	Formulary	Other	Tot. Unit	Unit	Allowed	Util/	Unit	Rate		Allowed
	Trend	Change	Change	Change	Cost Chg	Cost	PMPM	1000	Cost	PMPM	Credibility	PMPM
Retail Generic					0.000	\$0.00	\$0.00			\$0.00		\$0.00
Retail Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
Retail Non-Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
4. Retail Specialty					0.000	\$0.00	\$0.00			\$0.00		\$0.00
5. Mail Order Generic					0.000	\$0.00	\$0.00			\$0.00		\$0.00
Mail Order Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
7. Mail Order Non-Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
8. Mail Order Specialty					0.000	\$0.00	\$0.00			\$0.00		\$0.00
9. Total Retail	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
10. Total Mail Order	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
11. Total Generic	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
12. Total Brand (Preferred and Non-Preferred)	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00		\$0.00		0%	
13. Total Specialty	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
14. Total	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
									CMS Guidelii	ne Credibility	0%	

V. PMPM Non-Benefit Expenses	(e)
	Projected Expenses
Sales and Marketing	
2. Direct Administration	
3. Indirect Administration	
4. Net Cost of Private Reinsurance	
	·
5. Total Non-Benefit Expenses	\$0.00

VI. Percentage of Revenue	(j)
	at 0.000
1. Claims (Allowable Cost Target):	\$0.00
Non-Benefit Expenses	\$0.00
3. Gain/(Loss):	\$0.00
4. Total Basic Bid	\$0.00
5. Percentage of Revenue	
a. Claims (Allowable Cost Target):	0.0%
b. Non-Benefit Expenses	0.0%
c. Gain/(Loss):	0.0%

I. General Information

1. Contract Number:	4. Contract Yr:	2024	7. Plan Name:	10. VBID-D: N	12. PD Region:		15. PMM:	N
2. Plan ID:	5. Org. Name:		8. Plan Type:		13. PD Benefit Type:			
3. Segment ID:	6. SNP:		9. Enrollee Type:	11. ESRD-SNP: N	14. SNP Type:	N/A		

II. Projection Data

1. Projected Member Months:	0	2. Projected Avg Risk Score:	3. Projected LIS Member Months:	
			4. Projected non-LIS Member Months:	0

III. Part D Covered Drug Claims

	(d)	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(l)	(m)	(n)	(o)
Allowed					Avg Amt				Other			Federal
Claim	# of	Member	# of	Projected	Allowed		Gap	PMPM	Cost Sharing	Federal	Plan Liability	LICS
Interval	Members	Months	Scripts	Allowed	PMPM	Cost Sharing	PMPM	Deductible	PMPM	Reins. PMPM	PMPM	PMPM
1. \$0					\$0.00						\$0.00	
2. \$1-\$504					\$0.00	\$0.00					\$0.00	
3. \$505-\$4,659					\$0.00	\$0.00					\$0.00	
4. \$4,660-Catastrophic					\$0.00	\$0.00					\$0.00	
 Above Catastrophic 					\$0.00	\$0.00					\$0.00	
6. Subtotal	0	0	0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
					40.00				Ī	40.00	40.00	,
7. Minus Rebates					\$0.00				ļ	\$0.00	\$0.00]
8. Plus Part D as Secondary					\$0.00						\$0.00	
9. Projected % OON Included above:	Allowed:											
	Plan Liability:											
11. Total				\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

IV. Non-Benefit Expenses and Gain/(Loss)

1.	Basic Non-Benefit Expenses	\$0.00
2.	Supplemental Non-Benefit Expenses	\$0.00
3.	Total Non-Benefit Expenses	\$0.00
4.	Basic Gain/(Loss)	\$0.00
5.	Supplemental Gain/(Loss)	\$0.00
6.	Total Gain/(Loss)	

١.	Defined	Standard	Coverage	Bid	Deve	opment
----	---------	----------	----------	-----	------	--------

	(i)	(j)
	At 0.000	At 1.00
1. Claims (Allowable Cost Target):	\$0.00	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss):	\$0.00	\$0.00
4. Total Basic Bid	\$0.00	\$0.00
5. Federal Reinsurance:	\$0.00	\$0.00

7. Related-Party Allowed Cost PMPM	
8 Related-Party Non-Renefit Evnence PMPM	

Page 4 of 8

I. General Information

 Contract Number: 	Contract Yr:	2024	7. Plan Name:	10. VBID-D: N	12. PD Region:	15. PMM: N
2. Plan ID:	5. Org. Name:		8. Plan Type:		PD Benefit Type:	
Segment ID:	6. SNP:		9. Enrollee Type:	11. ESRD-SNP: N	14. SNP Type:	N/A

II. Projection Data

1. Projected Member months	0	Projected Avg Risk Score	0.000	

III. Development of Bid for Standard Coverage

	At 0.000	At 1.00
1. Claims (Allowable Cost Target)	\$0.00	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss):	\$0.00	\$0.00
4. Total Basic Bid	\$0.00	\$0.00
5. Federal Reinsurance	\$0.00	\$0.00
6. LIS	\$0.00	

V. Std. Cov. Bid Development with Actuarially Equivalent C. S.

	At 0.000	At 1.00
1. Claims (Allowable Cost Target)	\$0.00	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss):	\$0.00	\$0.00
4. Total Basic Bid	\$0.00	\$0.00
5. Federal Reinsurance	\$0.00	\$0.00
6. LIS		

IV: Development of Bid Components and Tests for Actuarial Equivalence

	(e)	(g)	(i)	(I)
1. Total Members				0
2. Member Months				0
	Amounts below	Amounts in	Amounts above	Row
	Initial Coverage Limit	Gap	Catastrophic Threshold	Subtotal
	<\$4,660			
Allowed PMPM				
3. Standard	\$0.00	\$0.00	\$0.00	\$0.00
4. Standard with Act. Equiv. Cost Sharing	\$0.00	\$0.00	\$0.00	\$0.00
5. Value of Deductible	\$0.00	\$0.00	\$0.00	\$0.00
Allowed Subject to Coins.				
6. Standard	\$0.00	\$0.00	\$0.00	\$0.00
7. Standard with Act. Equiv. Sharing	\$0.00	\$0.00	\$0.00	\$0.00
Coins. %				
8. Standard	25.0% A	0.0%	0.0% C	0.0%
9. Standard with Act. Equiv. Sharing	0.0% B	0.0%	0.0% D	0.0%
Coins PMPM				
10. Standard	\$0.00	\$0.00	\$0.00	\$0.00
11. Standard with Act. Equiv. Sharing	\$0.00	\$0.00	\$0.00	\$0.00
Net Cost of Benefit				
12. Standard	\$0.00	\$0.00	\$0.00	\$0.00
13. Standard with Act. Equiv. Sharing	\$0.00	\$0.00	\$0.00	\$0.00
Rebates			For Reinsurance	Inc Reins.
14. Standard			\$0.00	\$0.00
15. Standard with Act. Equiv. Sharing			\$0.00	
Test for Actuarial Equivalence				
Effective coinsurance with alternative cost sha	aring = to effective coinsurance for star	ndard cost sharing		
16. A=B	No			
17. C=D	No			
18. Coverage in the Gap	No			
19. Insulin	Yes			

Page 5 of 8

I. General Information

Contract Number	4. Contract Yr:	2024	7. Plan Name:	10. VBID-D:	N	12. PD Region:	15. PMM: N	
2. Plan ID:	5. Org. Name:		8. Plan Type:			13. PD Benefit Type:		
3. Segment ID:	6. SNP:		9. Enrollee Type:	11. ESRD-SNP:	N	14. SNP Type:	N/A	

II. Projection Data

 Projected Member months 	0	Projected Avg Risk Score	0.000	

III. Development of Bid for Standard Coverage

	At 0.000		At 1.00
1. Claims	\$0.00	С	\$0.00
2. Non-Benefit Expenses	\$0.00		\$0.00
3. Gain/(Loss)	\$0.00		\$0.00
4. Total Basic Bid	\$0.00		\$0.00
5. Federal Reinsurance	\$0.00		\$0.00
6. Total Coverage	\$0.00	Α	\$0.00
7. LIS	\$0.00		

V. Development of Actuarial Equivalence Test

	At 0.000	At 1.00
1. Part D Covered Drugs	\$0.00 D	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss)	\$0.00	\$0.00
4. Federal Reinsurance	\$0.00	\$0.00
5. Total Part D Covered	\$0.00 B	\$0.00
6. Non-Part D Covered Drugs	\$0.00	
7. Total Plan Coverage	\$0.00	
8. Total Basic Bid	\$0.00	\$0.00
9. LIS		

IV. Development of Bid Components

| (d) (f) (g) (i) (k) (m) (o) (q) | (q) |

	<\$4,660	>=\$4,660	for all members		Catastrophic	Members	
 Population not Meeting Deductible 	0	0	0		0	0	
Population Meeting Deductible	0	0	0		0	0	
3. Member Months	0	0	0		0	0	
	Туре	of Deductible		Type of Gap Coverage			Non-
	Alt Coverage Deduc	tible Amount		E Alternative Coverage ICL		Row	Part D
Allowed PMPM	Amounts be	low Initial Cove		Amts in Gap	Amts above Catastrophic	Subtotal	Covd
4. Standard	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
5. Alternative	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Deductible							
6. Value of \$505 Deductible	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
7. Value of Proposed Deductible	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Allowed Subject to Coins.							
8. Standard	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
9. Alternative	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Coins. %							
10. Standard	25.0%	25.0%	0.0%	100.0% J	0.0% H	4	0.0%
11. Alternative	0.0%	0.0%	0.0%	0.0%	0.0% I		0.0%
Coins PMPM							
12. Standard	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
13. Alternative	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Federal Reinsurance							
14. Standard					\$0.00	\$0.00	\$0.00
15. Alternative					\$0.00	\$0.00	\$0.00
Minus Rebates					For Reinsurance	Inc Reins.	
16. Standard					\$0.00	\$0.00	\$0.00
17. Alternative					\$0.00		
Plus Part D as Secondary							
18. Standard					\$0.00	\$0.00	\$0.00
19. Alternative							
Net Cost of Benefit							
20. Standard	\$0.00	\$0.00 F	•	\$0.00	\$0.00	\$0.00	\$0.00
21. Alternative	\$0.00	\$0.00 G	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

21. Alternative VI. Tests for Alternative Coverage:

1. Insulins	Yes
2. Total Coverage >= Std Coverage (B>=A)	Yes
Unsubsidized value>= Unsub Value for Std Covg(1=yes and D>=C)	Yes
 Average Cost at Initial Covg Limit >= Std (G >=F) 	Yes
5. Deductible <=\$505 (E <=505)	Yes
Average Catastrophic cost sharing <= Std (I <= H)	Yes
7. Coverage in the Gap (K <= J)	Yes

VIII. Development of Induced Utilization Adjustment

	At 0.000	At 1.00
1. Claims for Standard	\$0.00	\$0.00
2. Impact of Alternative Utilization on Standard		\$0.00
3. Allowable Cost Target for Alternative	\$0.00	\$0.00
4. Induced Utilization Adjustment	0.000	0.000

VII. Development of Supplemental Premium:

vii. Development of Supplemental Fremium.	
	At 0.000
1. Part D Covered Drugs	\$0.00
2. Non Part D Covered Drugs	\$0.00
3. Less Basic Covered	\$0.00
4. Supplemental Coverage	\$0.00
5. Reduction in Reinsurance	\$0.00
6. Additional Non-Benefit Expenses	\$0.00
7. Additional Gain/(Loss)	\$0.00
8. Supplemental Premium	\$0.00

WORKSHEET 6 - Rx SCRIPT PROJECTIONS FOR DEFINED STANDARD,	, ACTUAR	IALLI EQUIVALENI	OR ALTERNATIVE	COVERAGE			Page 6 o
I. General Information 1. Contract Number: 4. Co	ontract Yr:	2024	7 Plan Nama:		10. VBID-D:	N	12 DD Pagion:
	ontract Yr: org. Name:	2024	7. Plan Name: 8. Plan Type:		10. VBID-D:	N	 PD Region: PD Benefit Type
Segment ID: 6. SN			9. Enrollee Type:		11. ESRD-SNP:	N	14. SNP Type:
						413	
. Projections for Equivalence Tests		(f)	(g)	(h)	(i)	(j)	(k)
opulation Not Exceeding \$4,660 with Std Coverage			efined Standard Covera			ly Equivalent or Alternati	
Lines 1-9 exclude claims subject to deductible		Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
Retail Generic Retail Preferred Brand							
3. Retail Non-Preferred Brand							
4. Retail Specialty							
5. Mail Order Generic							
Mail Order Preferred Brand							
7. Mail Order Non-Preferred Brand							
8. Mail Order Specialty							
9. Total		0	\$0.00	\$0.00	0	\$0.00	\$0.
D. Claims Subject to Deductible							
opulation Exceeding \$4,660 with Std Coverage							
Lines 11-18 exclude claims subject to deductible		Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
11. Retail Generic		·					
12. Retail Preferred Brand							
13. Retail Non-Preferred Brand							
14. Retail Specialty							
15. Mail Order Generic							
16. Mail Order Preferred Brand							
17. Mail Order Non-Preferred Brand							
18. Mail Order Specialty							
19. Total		0	\$0.00		0	\$0.00	
). Claims Subject to Deductible							
Amounts Allocated Up to ICL (excluding claims subject to deductible)		Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
L. Retail Generic							
2. Retail Preferred Brand							
B. Retail Non-Preferred Brand I. Retail Specialty							
i. Mail Order Generic							
5. Mail Order Preferred Brand							
7. Mail Order Non-Preferred Brand							
8. Mail Order Specialty							
9. Total		0	\$0.00	\$0.00	0	\$0.00	\$0.
Amounts Allocated over Catastrophic Coverage		Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
). Retail Generic L. Retail Preferred Brand							
. Retail Non-Preferred Brand							
2. Retail Non-Preferred Brand 8. Retail Specialty							
2. Retail Non-Preferred Brand 3. Retail Specialty 1. Mail Order Generic							
. Retail Non-Preferred Brand . Retail Specialty . Mail Order Generic . Mail Order Preferred Brand							
. Retail Non-Preferred Brand . Retail Specialty . Mail Order Generic . Mail Order Preferred Brand . Mail Order Non-Preferred Brand							
2. Retail Non-Preferred Brand 3. Retail Specialty 1. Mail Order Generic 5. Mail Order Preferred Brand 6. Mail Order Non-Preferred Brand 7. Mail Order Specialty		0	\$0.00	\$0.00	0	\$0.00	\$0.
. Retail Non-Preferred Brand . Retail Specialty . Mail Order Generic . Mail Order Preferred Brand . Mail Order Non-Preferred Brand . Mail Order Specialty			\$0.00	\$0.00	•	\$0.00	
. Retail Non-Preferred Brand . Retail Specialty . Mail Order Generic . Mail Order Preferred Brand . Mail Order Non-Preferred Brand . Mail Order Specialty . Total		0 Number of Scripts	\$0.00 Allowed \$	\$0.00 Std Cost Sharing \$	0 Number of Scripts	\$0.00 Allowed \$	
. Retail Non-Preferred Brand . Retail Specialty . Mail Order Generic . Mail Order Preferred Brand . Mail Order Non-Preferred Brand . Mail Order Specialty . Total				-	•		
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending	RK PRICING	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending	RK PRICING	Number of Scripts GEN	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending		Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending	RETAIL	Number of Scripts GEN discount off AWP	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	ALTY
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending		Number of Scripts GEN discount off AWP	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI	RETAIL	Number of Scripts GEN % discount off AWP	Allowed \$ ERIC Dispensing Fee	Std Cost Sharing \$ BRA % discount off AWP	Number of Scripts ND Dispensing Fee	Allowed \$ SPECI % discount off AWP	Cost Sharing \$ ALTY Dispensing Fee
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI	RETAIL	Number of Scripts GEN % discount off AWP	Allowed \$ ERIC Dispensing Fee	Std Cost Sharing \$ BRA % discount off AWP	Number of Scripts ND Dispensing Fee (i)	Allowed \$ SPECIA % discount off AWP	Cost Sharing \$ ALTY Dispensing Fee
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection	RETAIL	Number of Scripts GEN % discount off AWP (f) D	Allowed \$ ERIC Dispensing Fee	Std Cost Sharing \$ BRA % discount off AWP (h)	Number of Scripts ND Dispensing Fee (i) Actuarial	Allowed \$ SPECI % discount off AWP	Cost Sharing \$ ALTY Dispensing Fee
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin	RETAIL	Number of Scripts GEN % discount off AWP (f) D. Number of 30-Day	Allowed \$ ERIC Dispensing Fee	Std Cost Sharing \$ BRA % discount off AWP	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day	Allowed \$ SPECIA % discount off AWP	Cost Sharing \$ ALTY Dispensing Fee
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval	RETAIL	Number of Scripts GEN % discount off AWP (f) D	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera	Std Cost Sharing \$ BRA % discount off AWP (h)	Number of Scripts ND Dispensing Fee (i) Actuarial	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage	RETAIL	Number of Scripts GEN % discount off AWP (f) D. Number of 30-Day	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera	Std Cost Sharing \$ BRA % discount off AWP (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORN Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage	RETAIL	Number of Scripts GEN % discount off AWP (f) D. Number of 30-Day	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera	Std Cost Sharing \$ BRA % discount off AWP (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORK Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL	RETAIL	Number of Scripts GEN % discount off AWP (f) D. Number of 30-Day	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera	Std Cost Sharing \$ BRA % discount off AWP (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage	RETAIL	Number of Scripts GEN % discount off AWP (f) D. Number of 30-Day	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera	Std Cost Sharing \$ BRA % discount off AWP (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k)
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORN Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL	RETAIL	Number of Scripts GEN % discount off AWP (f) D. Number of 30-Day	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera	Std Cost Sharing \$ BRA % discount off AWP (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL Amounts in the Gap	RETAIL	Number of Scripts GEN % discount off AWP (f) D. Number of 30-Day Scripts	Allowed \$ ERIC Dispensing Fee (g) glined Standard Covera Allowed \$	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati Allowed \$	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL Amounts in the Gap Vaccines	RETAIL	Number of Scripts GEN % discount off AWP (f) Number of 30-Day Scripts (f)	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera Allowed \$	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts (i)	Allowed \$ SPECIA % discount off AWP (j) y Equivalent or Alternati Allowed \$	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$
Retail Non-Preferred Brand Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Mail Order Specialty Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL Amounts in the Gap Vaccines Projection	RETAIL	Number of Scripts GEN % discount off AWP (f) Number of 30-Day Scripts (f)	Allowed \$ ERIC Dispensing Fee (g) glined Standard Covera Allowed \$	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts (i)	Allowed \$ SPECI % discount off AWP (j) ty Equivalent or Alternati Allowed \$	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$
Retail Specialty Retail Specialty Mail Order Generic Mail Order Preferred Brand Mail Order Non-Preferred Brand Total Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL Amounts in the Gap Vaccines	RETAIL	Number of Scripts GEN % discount off AWP (f) Number of 30-Day Scripts (f) (f) D	Allowed \$ ERIC Dispensing Fee (g) effined Standard Covera (g) (g)	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts (i) Actuariall	Allowed \$ SPECIA % discount off AWP (j) ly Equivalent or Alternati Allowed \$ (j) ly Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$ (k)
2. Retail Non-Preferred Brand 3. Retail Specialty 4. Mail Order Generic 5. Mail Order Preferred Brand 6. Mail Order Non-Preferred Brand 7. Mail Order Specialty 8. Total 9. Non-Part D Covered Drugs - All Spending NETWORI Linsulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL Amounts in the Gap 1. Vaccines Projection Interval Projection Interval	RETAIL	Number of Scripts GEN % discount off AWP (f) Number of 30-Day Scripts (f)	Allowed \$ ERIC Dispensing Fee (g) fined Standard Covera Allowed \$	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$ (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts (i)	Allowed \$ SPECIA % discount off AWP (j) y Equivalent or Alternati Allowed \$	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$
2. Retail Non-Preferred Brand 3. Retail Specialty 4. Mail Order Generic 5. Mail Order Preferred Brand 6. Mail Order Non-Preferred Brand 7. Mail Order Specialty 8. Total 9. Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL Amounts in the Gap 1. Vaccines Projection Interval Population Not Exceeding \$4,660 with Std Coverage	RETAIL	Number of Scripts GEN % discount off AWP (f) Number of 30-Day Scripts (f) (f) D	Allowed \$ ERIC Dispensing Fee (g) effined Standard Covera (g) (g)	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$ (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts (i) Actuariall	Allowed \$ SPECIA % discount off AWP (j) ly Equivalent or Alternati Allowed \$ (j) ly Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$ (k)
2. Retail Specialty 3. Retail Specialty 4. Mail Order Generic 5. Mail Order Preferred Brand 6. Mail Order Preferred Brand 7. Mail Order Specialty 8. Total 7. Mail Order Specialty 8. Total 7. Non-Part D Covered Drugs - All Spending 8. Non-Part D Covered Drugs - All Spending 8. Insulin 8. Insulin 8. Projection 8. Interval 9. Population Not Exceeding \$4,660 with Std Coverage 9. Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL 9. Amounts in the Gap 8. Vaccines 8. Projection 8. Interval 9. Population Not Exceeding \$4,660 with Std Coverage 9. Population Exceeding \$4,660 with Std Coverage 9. Population Not Exceeding \$4,660 with Std Coverage 9. Population Not Exceeding \$4,660 with Std Coverage 9. Population Exceeding \$4,660 with Std Coverage 9. Population Exceeding \$4,660 with Std Coverage	RETAIL	Number of Scripts GEN % discount off AWP (f) Number of 30-Day Scripts (f) (f) D	Allowed \$ ERIC Dispensing Fee (g) effined Standard Covera (g) (g)	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$ (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts (i) Actuariall	Allowed \$ SPECIA % discount off AWP (j) ly Equivalent or Alternati Allowed \$ (j) ly Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$ (k)
2. Retail Non-Preferred Brand 3. Retail Specialty 4. Mail Order Generic 5. Mail Order Preferred Brand 6. Mail Order Non-Preferred Brand 7. Mail Order Specialty 8. Total 9. Non-Part D Covered Drugs - All Spending NETWORI Insulin Projection Interval Population Not Exceeding \$4,660 with Std Coverage Population Exceeding \$4,660 with Std Coverage Amounts Allocated Up to ICL Amounts in the Gap 7. Vaccines Projection Interval Population Not Exceeding \$4,660 with Std Coverage	RETAIL	Number of Scripts GEN % discount off AWP (f) Number of 30-Day Scripts (f) (f) D	Allowed \$ ERIC Dispensing Fee (g) effined Standard Covera (g) (g)	Std Cost Sharing \$ BRA % discount off AWP (h) ge Std Cost Sharing \$ (h)	Number of Scripts ND Dispensing Fee (i) Actuariall Number of 30-Day Scripts (i) Actuariall	Allowed \$ SPECIA % discount off AWP (j) ly Equivalent or Alternati Allowed \$ (j) ly Equivalent or Alternati	Cost Sharing \$ ALTY Dispensing Fee (k) ve Benefits Cost Sharing \$ (k)

15. PMM: N

WORKSHEET 6A - COVERAGE IN THE GAP

I. General Information								
Contract Number:	4. Contract Yr:	2024	7. Plan Name:		10. VBID-D:	N	12. PD Region:	15. PMM: N
2. Plan ID:	5. Org. Name:		8. Plan Type:				13. PD Benefit Type	c
3. Segment ID:	6. SNP:		Enrollee Type:		11. ESRD-SNP:	N	14. SNP Type:	N/A
II. Spending in the Coverage Gap		(f)	(g)	(h)	(i)	(j)	(k)	
Population Exceeding \$4,660 with Std Coverage			Defined Standard Coverag	je	Actuaria	ally Equivalent or Al	ternative Benefits	

I. Spending in the Coverage Gap	(f)	(g)	(h)	(i)	(j)	(k)
Population Exceeding \$4,660 with Std Coverage	D	Defined Standard Coverage		Actuarially Equivalent or Alternative Benefits		e Benefits
Amounts Allocated between \$4,660 and Catastrophic	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
. Retail Generic	0	\$0.00	\$0.00	0	\$0.00	\$0.
2. Retail Preferred Brand	0	\$0.00	\$0.00	0	\$0.00	\$0.
B. Retail Non-Preferred Brand	0	\$0.00	\$0.00	0	\$0.00	\$0.
I. Retail Specialty Generic	0	\$0.00	\$0.00	0	\$0.00	\$0.
5. Retail Specialty Brand	0	\$0.00	\$0.00	0	\$0.00	\$0
6. Mail Order Generic	0	\$0.00	\$0.00	0	\$0.00	\$0
7. Mail Order Preferred Brand	0	\$0.00	\$0.00	0	\$0.00	\$0
Mail Order Non-Preferred Brand	0	\$0.00	\$0.00	0	\$0.00	\$0
Mail Order Specialty Generic	0	\$0.00	\$0.00	0	\$0.00	\$0
Mail Order Specialty Brand	0	\$0.00	\$0.00	0	\$0.00	\$0
1. Total	0	\$0.00	\$0.00	0	\$0.00	\$0
Low Income Population Amounts Allocated between \$4,660 and Catastrophic						
	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
2. Retail Generic						
Retail Preferred Brand						
Retail Non-Preferred Brand						
5. Retail Specialty Generic						
6. Retail Specialty Brand						
7. Mail Order Generic						
Mail Order Preferred Brand						
Mail Order Non-Preferred Brand						
0. Mail Order Specialty Generic						
1. Mail Order Specialty Brand						
22. Total	0	\$0.00	\$0.00	0	\$0.00	\$0
Non-Low Income Population Amounts Allocated between \$4,660 and Catastrophic						
	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$
3. Retail Generic						
4. Retail Preferred Brand						
5. Retail Non-Preferred Brand						
6. Retail Specialty Generic						
7. Retail Specialty Brand						
8. Mail Order Generic						
9. Mail Order Preferred Brand						
0. Mail Order Non-Preferred Brand						
Mail Order Specialty Generic						
2. Mail Order Specialty Brand						
33. Total	0	\$0.00	\$0.00	0	\$0.00	\$0

Non-LI Generics in Gap PMPM Non-LI Brand Discount Amt PMPM \$0.00 **\$0.00**

I. General Information

ŀ	Contract Number:	4. Contract Yr: 2024	7. Plan Name:	10. VBID-D:	N	12. PD Region:	15. PMM: N
	2. Plan ID:	5. Org. Name:	8. Plan Type:			13. PD Benefit Type:	
;	3. Segment ID:	6. SNP:	9. Enrollee Type:	11. ESRD-SNP:	N	14. SNP Type: N/A	

II. 2024 Defined Standard Benefit Parameters

1. Deductible	\$505
2. Initial Coverage Limit	\$4,660
3. Out-of-pocket Limit	\$7,400

III. Summary of Key Bid Elements

iii. Gaiiiiiai y Gi Noy Bia Eiginoitio	
1. Standardized Part D Bid	\$0.00
2. National Average Monthly Bid Amount	
3. Base Beneficiary Premium	
Basic Part D Premium (prior to A/B rebate allocation)	
4. Unrounded	\$0.00
5. Rounded	\$0.00
Supplemental Part D Premium (prior to A/B rebate allocation)	
6. Unrounded	\$0.00
7. Rounded	\$0.00
Prospective federal reinsurance (non-standardized)	\$0.00
Prospective low-income cost sharing subsidy (non-standardized)	\$0.00
10. Target amount adjustment (allowed costs as a ratio of bid)	1.0000
11. Prospective brand discount amount	\$0.00
Rounding Rule	
12. Round Part D premiums to nearest	\$0.10

IV Part D Pid Prining Tool Contacts

IV. Part D Bid Pricing Tool Cor	ıtacts
Plan Bid Contact	
Name	
Phone	
Email	
Part D Certifying Actuary	
Name and Credentials	
Phone	
Email	
Part D Additional BPT Actuaria	l Contact
Name	
Phone	
Email	
Date Prepared	

V. Working Model Text Box

This section can be used at the discretion of the Plan sponsor. The contents are NOT uploaded in the bid submission.
The contents are NOT uploaded in the bid submission.